0001209191-19-058104.txt : 20191126 0001209191-19-058104.hdr.sgml : 20191126 20191126161510 ACCESSION NUMBER: 0001209191-19-058104 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191125 FILED AS OF DATE: 20191126 DATE AS OF CHANGE: 20191126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Sung CENTRAL INDEX KEY: 0001793200 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 191251037 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001793200 Lee Sung 7000 MARINA BLVD. BRISBANE CA 94005 0 1 0 0 EVP, Chief Financial Officer Common Stock 2019-11-25 4 A 0 43750 0.00 A 43750 D Stock Option (Right to Buy) 10.35 2019-11-25 4 A 0 262000 0.00 A 2029-11-24 Common Stock 262000 262000 D Includes 43,750 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 25, 2019. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service with the Issuer through such date. One-quarter (1/4) of the option shares vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the November 25, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Matthew Colvin, Attorney-in-Fact for Sung Lee 2019-11-26